Emyria

Emyria has secured the exclusive rights to a library of more than 100 novel MDMA analogues from the University of Western Australia creating what it describes as a unique drug-discovery pipeline.

Emyria MD Dr Michael Winlo

The library has been developed by the research group of medicinal chemist Dr Matt Piggott, who has been working with MDMA analogues, and exploring their therapeutic potential, for more than 10 years.

Emyria aims to screen and expand the existing library in order to identify families of patentable compounds with the greatest promise.

Managing director Dr Michael Winlo said: “This agreement creates an opportunity for Emyria to lead the development of the next generation of MDMA-like compounds so they may become registered treatments for patients with major psychiatric and neurological disorders.”

Medibis

Queensland-based Medibis has raised more than A$1m in crowdfunding, attracting $1.26m from 519 investors.

The company plans to launch a range of cannabinoid formulations via global partner BOL Pharma and eventually build a $180m manufacturing facility near Toowoomba.

Director Angus Chapel said: “We’ve been blown away by the support from our community – those in the Toowoomba area are about twice as enthusiastic as the average investor. It’s so exciting to have such incredible support behind our mission.”

Incannex Healthcare

Incannex Healthcare has completed a Human Research Ethics Committee submission for a phase 2a Psi-GAD study which aims to combine psilocybin with specialised therapy for patients with Generalised Anxiety Disorder (GAD).

The company has also submitted a comprehensive information package to the US Food and Drug Administration (FDA) to request a pre-Investigational New Drug meeting.

The submission seeks regulatory clarity from the FDA on Incannex’s planned phase 2b Psi-GAD clinical trial.

Eqalis Pharmaceuticals

Eqalis chief medical officer Elizabeth Plant

Eqalis Pharmaceuticals is getting ready to ramp up manufacturing capacity at its KatiKati operations by raising NZ$7 million in new equity in its latest private funding round. 

The funding round included two tranches, with the paperwork for the final $1.6 million to be completed shortly as the bulk of the money was raised in July. 

This is the fifth round of funding since Eqalis was incorporated in January 2019.

Greenfern Industries 

Taranaki-based therapeutic medicinal cannabis firm Greenfern Industries is crowdfunding ahead of its initial public offering (IPO). Greenfern is looking to raise a minimum NZ$2 million and as much as $3 million ahead of a planned IPO on the NZX later this year.

Creso Pharma

Creso Pharma Canadian subsidiary Mernova has been granted a new sales licence, meaning the company can now sell medicinal cannabis products directly to consumers.

Previously, Health Canada only allowed the company to sell its medicinal cannabis products to wholesalers or directly to recreational cannabis users.

Under the Ritual Green and Ritual Sticks brand, Mernova has received CA$224,580 worth of purchase orders for products.

Highlands Investments

Highlands Investments managing director Mark Corbett

Lesotho-based Highlands Investments has secured the sale of 8.5 tonnes of THC and CBD flower and trim to the European medicinal cannabis market.

The new shipment follows a previously successful shipment of 176.5kg of THC flower to Europe in April.

Managing director Mark Corbett said: “We believe this to be one of the largest legal shipments of medical grade cannabis to date and is a significant milestone for our business.”